Evidence map›Paper›PMID 41999083›Full record

ReviewMediators of inflammation2026

The Role of the C3a-C3aR Pathway in Diseases: Latest Research Advances.

Xiangwei Bo, Mi Wang, Yang Liu, Yong Zhong

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiangwei BoDepartment of Health Medicine, Affiliated Jinling Hospital, School of Medicine, Nanjing University, Nanjing, 210002, China, nju.edu.cn.ORCID https://orcid.org/0000-0001-9436-112X
Mi WangDepartment of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, 87 Dingjiaqiao, Nanjing, 210009, China, seu.edu.cn.ORCID https://orcid.org/0009-0005-4833-6122
Yang LiuDepartment of Critical Care Medicine, Affiliated Jinling Hospital, School of Medicine, Nanjing University, Nanjing, 210002, China, nju.edu.cn.ORCID https://orcid.org/0000-0002-1683-1859
Yong ZhongDepartment of Health Medicine, Affiliated Jinling Hospital, School of Medicine, Nanjing University, Nanjing, 210002, China, nju.edu.cn.ORCID https://orcid.org/0000-0003-4785-8285

Funding

Jiangsu Province Key Project for Cadre Healthcare BJ2407
6 · The paper itself

Abstract

C3a is a key active factor in the complement system, capable of participating in various physiological and pathological processes by binding to its C3a receptor (C3aR). The C3a-C3aR pathway not only plays an important role in immune regulation but is also closely related to the occurrence and development of various inflammatory diseases, cardiovascular diseases, autoimmune diseases, and tumors. In recent years, research on the specific mechanisms of action of C3a-C3aR in different diseases has gradually deepened. This article aims to review the basic functions of the C3a-C3aR pathway, with a focus on summarizing the latest research advances in kidney diseases, cardiovascular diseases, neurodegenerative diseases, autoimmune diseases, and tumors, and to explore its prospects as a potential therapeutic target.

Indexed as

Complement C3aReceptors, ComplementAnimalsAutoimmune DiseasesCardiovascular DiseasesHumansInflammationKidney DiseasesNeoplasmsNeurodegenerative DiseasesSignal TransductionComplement C3acomplement C3a receptorReceptors, Complementautoimmune diseasesC3a-C3aR pathwaycancercardiovascular diseasesinflammationkidney diseasesneurodegenerative diseasestherapeutic target

Identifiers

PMID41999083
PMCPMC13090565

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.